was ist denn da los.? kann einer von Euch was zu dem Wert - 500 Beiträge pro Seite

[williaktie]

sagen. wie seht ihr deren Kursverlauf für die nächsten Monate.
mfg

[williaktie]

keiner da,alle sauer über die Börse.???
denke persönlich illumina wird wieder an die 10.- laufen,so,nun macht mich fertig""" mein KK, war 3,6
bin mal gespannt,wann wir die 10.- oder mehr sehen.
schönes WE euch allen und einen besseren Börsenverlauf für den Rest des Jahres, """"""" Jahresendrally,kommt sie unverhofft.???? möglich ist es,da keiner "" es erwartet!!
williaktie

[klatschi]

Jahresendrally,kommt sie unverhofft.???? möglich ist es,da keiner "" es erwartet!!

soso keiner erwartet sie aber du? ...glaub mir es gibt genug narren die selbst mitten in den schlimmsten crashs an eine rallye glauben! und es gibt ebenso genug leute die anderen leuten einreden das eine rallye immer dann kommt wenn keiner damit rechnet... insbesondere massenmedien neigen oft dazu solchen blödsinn zu verbreiten... und weisst du auch warum? ich erklärs dir.............. ach shit ich muss weg

[meislo]

Enabling Pharmacogenomics: Survey Shows Researchers Looking for New Solutions
Thursday October 17, 12:57 pm ET


ARLINGTON, Va., Oct. 17 /PRNewswire/ -- According to a recent survey, Applied Biosystems (NYSE: ABI - News), Affymetrix (Nasdaq: AFFX - News), Illumina (Nasdaq: ILMN - News), Orchid Biosciences (Nasdaq: ORCH - News), Sequenom (Nasdaq: SQNM - News) and QIAGEN (Nasdaq: QGENF - News) are the companies scientists most closely associate with the fast-growing market for products and services related to SNP genotyping. More than 540 researchers currently studying single nucleotide polymorphisms (SNPs) were surveyed by BioInformatics, LLC (Arlington, VA), a leading provider of market research to the biotechnology industry.
ADVERTISEMENT


In a new report, "The Market for SNP Products and Services: Enabling Pharmacogenomics," BioInformatics explores why scientists choose one genotyping method over another, what products and services they are buying, and the challenges they continue to face. Looking at the entire market potential, the report not only reflects the experience and opinions of 377 scientists who currently perform SNP genotyping in their own labs, but also 166 others who primarily outsource their SNP genotyping.

The results of the survey reveal a fast growing segment of the life science market as over half of the respondents expect to increase their level of SNP genotyping over the next 12 months. "SNPs are the focus of so much attention in the pharmaceutical industry because they provide a powerful approach to understanding the connection between genetic variation and its physical manifestation," explains Dr. Tamara Zemlo, senior science advisor for BioInformatics. "Understanding the role of genetic variation is expected to profoundly change our understanding of human disease and the practice of medicine in the years to come."

The enormous number of SNPs currently being discovered as a result of whole genome association studies is prompting industry to develop new technologies emphasizing ever-higher throughput and cost effectiveness. At the same time, however, the report clearly demonstrates that the products a scientist chooses to detect mutations will vary greatly depending on the scale and scientific question he or she is trying to answer.

For example, when deciding what method to use for SNP genotyping, "accuracy" is the most important feature sought by an overwhelming 87% of the scientists who currently perform SNP genotyping in their own lab. Of all the SNP genotyping methods available, 62% of these 377 respondents employ sequencing -- a technique that offers researchers the highest degree of specificity and selectivity due to its redundancy.

"Sequencing`s `gold standard` status is due in part to the fact that the validity of most other SNP genotyping techniques has been evaluated by comparing the level of agreement of their results with the results based upon sequencing," hypothesizes Dr. Robin Rothrock, BioInformatics` Director of Market Research. "Another attraction of this technique is its relative ease and its availability to many researchers."

The report suggests that when trying to decide among the many SNP genotyping methods available, scientific customers can become easily overwhelmed by their options -- from the selection of which molecular technique to use, to a myriad of choices for labeling, detection and scoring.

"The results of this survey clearly highlight the complexity of the market for both scientists and suppliers," says Rothrock. "Scientists want tools to improve accuracy and throughput coupled with enhanced cost effectiveness, but they`re willing to make trade-offs based on the goals of their research. Better software is also needed, not only for allele-calling, but for solutions that provide enhanced data analysis capabilities."

Rothrock concludes, "Given the current state of the market for SNP genotyping products and services, suppliers will most likely gain a competitive advantage when they focus on a specific niche and stay attuned to the evolving needs of their customers."

ABOUT BIOINFORMATICS, LLC

BioInformatics, LLC is a market research firm located in Arlington, Virginia. BioInformatics supports marketing, sales and R&D executives in the life science, medical device and pharmaceutical industries through published research reports, custom research and consulting. BioInformatics sponsors the world`s largest market research panel of scientific customers -- The Science Advisory Board (http://www.scienceboard.net ) -- which consists of more than 13,000 scientists, physicians and other life science and medical professionals from 62 countries who participate in surveys that address emerging technologies, test customer reactions to new product concepts, measure brand awareness and assess advertising effectiveness.

[meislo]

G Source: Illumina Inc.


Illumina Selected by the National Institutes of Health to Participate in the International HapMap Project
Tuesday October 29, 2:16 pm ET
Illumina One of Five Principal U.S. Research Groups Contributing to Project


SAN DIEGO--(BUSINESS WIRE)--Oct. 29, 2002--Illumina, Inc. (Nasdaq:ILMN - News) announced today that it will play a significant role in the International HapMap Project, a global consortium aimed at creating a detailed map of genetic variation and speeding the discovery of genes related to common disease. The role of Illumina and other principal research groups in the International HapMap Project was outlined today in a news briefing conducted by the International HapMap consortium and follows Illumina`s previous announcement regarding this $9 million HapMap-related genotyping award.
ADVERTISEMENT


Illumina is one of five funded U.S. HapMap Project participants in a $100 million worldwide initiative that includes research groups in Canada, China, Japan, Nigeria and the United Kingdom. Illumina`s team, led by Mark Chee, Ph.D. and in collaboration with the Wellcome Trust Sanger Institute and the Wellcome Trust Centre for Human Genetics, Oxford University, expects to map the common haplotypes in 15% of the human genome as part of the Project.

U.K.-based Sanger Institute and Oxford University will work closely with Illumina, providing expertise particularly in the areas of study design, SNP selection, and data analysis. Earlier this year, Illumina announced that it was conducting jointly with the Sanger Institute a pioneering study to provide a detailed haplotype map of a large chromosomal region. Well underway, the study is leveraging the Institute`s extensive SNP collection and Illumina`s BeadArray(TM) technology for cost-effective, production-scale genotyping. Results from this collaboration will help guide strategy for the international HapMap Project.

According to Jay Flatley, Illumina President and CEO, "We`re honored that the NIH has entrusted such a significant portion of the HapMap Project to Illumina and to our genotyping service team. We believe that BeadArray technology is ideally suited to satisfy the throughput, accuracy, and cost demands of the HapMap Project, and we look forward to working closely with the other participants to create a high-quality and freely accessible HapMap."

Mark Chee, Ph.D., Illumina Research Fellow, will represent Illumina on the HapMap Steering committee and liaise with other Project participants and collaborators to develop and execute HapMap strategy.

When completed, the HapMap will constitute a seminal reference work, aiding researchers in the evaluation of patient disease risks and therapeutic response based on individual genetic patterns.

Haplotypes are sets of single nucleotide polymorphisms (SNPs) that are linked. They identify human chromosomal DNA regions that are shared between individuals, and in some cases are associated with predispositions to specific diseases. A haplotype map of the human genome will allow more rapid and efficient large-scale genetic association studies aimed at discovering common genetic variants contributing to human disease and differential response to drug treatments. When deployed on an individual basis, HapMap information may lead ultimately to the advent of widespread personalized medicine.

Illumina (NASDAQ: ILMN; www.illumina.com) is developing next-generation tools that will permit large-scale analysis of genetic variation and function. The Company`s proprietary BeadArray(TM) technology provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements are Illumina`s ability to further develop its core BeadArray technologies for high-throughput genetic analysis, its ability to continue to manufacture oligonucleotides in sufficient quantity, and other factors detailed in the Company`s filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.
anz frisch aus der Presse

[meislo]

Nicht viel aber immerhin etwas

Illumina Inc.: Market Outperformer
31.10.2002 11:45:16
Die Analysten von Goldman Sachs stufen in ihrer Analyse vom 30.10. die Illumina Inc. weiterhin mit „Market Outperformer“ ein.
Aufgrund geringerer Ausgaben für Forschung&Entwicklung habe das US-Biotechunternehmen im dritten Quartal einen Verlust je Aktie von 0,24 Dollar ausgewiesen. Dies sei aber 0,05 Dollar besser als von den Analysten erwartet. Im Zuge dessen hätten die Analysten ihre Schätzung für den Jahresverlust 2002 um diese 0,05 Dollar auf 1,08 Dollar revidiert.

[meislo]

ILMN wird nicht mehr so stark geshortet !!


Short Interest



ILMN
Illumina, Inc. Nasdaq-NM



a= Date
b= Short Interest= Anzahl der geshorteten Aktien
in einem Monat
c= Avg Daily= Durschnittliches Handelsvolumen an Aktien
pro Tag
d= Share Volume Days
to Cover = b dividiert durch c ergibt d

---------a----------------b------------c----------d

Oct. 15, 2002-------431,766-----70,825------ 6.10
Sep. 13, 2002-------873,962-----42,579------20.53
Aug. 15, 2002-------882,312-----44,206------19.96
Jul. 15, 2002-------993,457-----88,244------11.26
Jun. 14, 2002-------985,768-----74,535------13.23
May 15, 2002 ------1,098,785----89,590------12.26
Apr. 15, 2002-------939,607----105,592------ 8.90
Mar. 15, 2002-------771,934-----75,031------ 9.08
Feb. 15, 2002-------796,207-----72,625------10.96
Jan. 15, 2002-------600,586-----50,990------11.78
Dec. 14, 2001-------525,199-----72,995------ 7.20
Nov. 15, 2001 465,422-----99,650------ 4.67





Data source: The Nasdaq Stock Market, Inc.





Short selling is the selling of a security that the seller does not own, or any sale that is completed by the delivery of a security borrowed by the seller. Short selling is a legitimate trading strategy.

Typically, a short sale involves the sale of a security at the current price which is settled with shares lent to the short seller by a third party. The seller makes the short sale on the assumption that the price of the security will go down. If this occurs, the short seller will purchase shares to lock in a profit, extinguish the short position and replace the shares previously borrowed.

Of course, if the stock rises in price, the short seller may elect to close out the position through a purchase, and absorb the resulting loss.

Firms are required to report their short positions as of settlement on the 15th of each month. A compilation is published eight business days after.



© Copyright | Disclaimer | Trademarks | Privacy Statement | Contact Us | Help | Search